Design and optimization of various antibody scaffolds and Fc-region modifications to enhance binding affinity and half-life for research models.
Learn More →Bispecific Antibody (BsAb) Therapy Development Services
Creative Biolabs offers an end-to-end pipeline designed for researchers seeking high-precision multi-targeting tools. We provide custom design, high-throughput expression, and rigorous biophysical analysis to ensure your candidates are structurally sound and functionally active. By leveraging our expertise, clients gain access to optimized antibody scaffolds with superior heterodimerization, enabling more accurate data generation and faster progression through the discovery pipeline.
Introduction What We Can Offer How We Can Help Why Choose Us? Customer Reviews FAQs Related Services Contact Us
Bispecific Antibodies: Engineered Immune Bridges
A bispecific antibody (BsAb) is an artificial antibody that can simultaneously bind two separate, specific antigens or different epitopes of the same antigen and establish a bridge between target cells and functional molecules to stimulate a directed immune response. This genetically engineered antibody has become a research hotspot in the field of antibody engineering and has an extensive prospect in immunotherapy for various diseases.
BsAbs do not exist in nature and thus they are produced by molecular, genetic, or biochemical approaches. With the evolving of technology of recombinant protein derivatives, many BsAbs have become therapeutic proteins. In Creative Biolabs, our proprietary BsAb technology constitute a suite of highly flexible platforms with multiple valuable options, eliminating the drug development challenge and offering attractive therapeutics for tumors.
Request a Consultation →
Fig.1 Bispecific antibody structure and function. 1,3
Bispecific Antibody Platforms at Creative Biolabs
Fig.2 Some classic structures of BsAbs with CD3 as one of their targets. 2,3
BsAb is the next generation of antibody therapeutics, which combines two or more antigen-recognizing elements into a single framework, and can bind to two or more target cells. It accounts for a theory that more than one pathway is usually at the root of disease. Creative Biolabs has advanced recombinant antibody technology and many other technology platforms to effectively immortalize the best hybridoma clones, which helps extend our antibody production and engineering capability.
BsAb Construction Platforms
The key point of BsAbs is that they bind two antigens simultaneously, leading to a wide range of concepts for the construction of various version of this antibody. As a result, a large number of tools for manufacturing BsAb are gradually emerging. Nowadays, the application of BsAbs has been expanded from conventional cancer immunotherapy to other diseases, such as AIDS, infections, and genetic diseases.
Quadroma technology
It allows to produce antibodies in a single host cell but results in a mixture of tailored and other unfunctional compounds.
CrossMab technology
It is based on the exchanging light chain and heavy chain domains within a unique Fab arm to induce special interaction while maintaining the original antigen binding affinity.
Linkers technology
Conjunction two parts of antibody fragment via specific linkers with different lengths.
Molecular cloning technology
Multiple DNA components are assembled to direct their replication within host cells.
Knobs-into-holes (KIH) technology
It is employed to force heavy chain of antibody heterodimerization over homodimerization.
Asymmetric re-engineering technology (ART)
A novel technique is invented by Japan scientists for asymmetric BsAbs.
Other Unique BsAb Platforms
The practice of research and diversity of antibody forms have explained that a unique BsAb format cannot meet all requirements. There are several examples of formats in preclinical or clinical trials indicating the strong potential of this type of compounds as biotherapeutics.
sdAb
Bispecific antibody fragment, its bispecificity obtained by connecting two sdAbs by short linkers;
κλ-BODY
Bispecific IgG, a fully human bispecific IgG antibody;
SEEDbody
Bispecific IgG-like, strand-exchange engineered domain is an alternation of human IgG and IgA sequence in the CH3 domain.
Creative Biolabs possesses seasoned experts and long-term experience in the development of all kinds of therapeutic antibodies. With the help of us, clients can select the optimal BsAb products and obtain the very detailed of the scientific knowledge linked to the antibody field.
Types of Our Services
In Creative Biolabs, we have designed and manufactured a variety of BsAbs through our powerful, open-access techniques, and the further development can be expected to successfully take BsAb approaches forward. Our services included but not limited to:
Bispecific Antibody Engineering
Bispecific Antibody Generation
Providing end-to-end solutions from sequence synthesis to stable cell line development utilizing advanced research platforms.
Learn More →Bispecific Antibody Analysis
Providing exhaustive biophysical characterization and functional assays to validate purity, structural integrity, dual-targeting affinity, and biological potency for research leads.
Learn More →Highlights
Stands at the intersection of biological innovation and manufacturing excellence. Our platforms are designed to de-risk your project at the discovery stage, ensuring that research concepts translate into stable, high-performance molecules.
Time-saving and Cost-efficient
Our streamlined engineering pipeline saves at least 6 months of development time and reduces experimental costs by half, allowing for rapid project advancement.
Versatile & High-Yield Platforms
We accommodate almost any mAb sequence to build symmetric or asymmetric molecules, achieving expression titers of 5-15 g/L in optimized HEK293 or CHO mammalian systems.
Advanced Purification & Quality
Utilizing multi-modal chromatography (Protein A/G, IEX) to achieve >95% purity, we deliver highly stable and soluble research leads (> 30 mg/ml) with low immunogenicity.
Rigorous QC Analysis
Every candidate undergoes rigorous testing, including mass spectrometry, SEC-HPLC, endotoxin tests, and activity assays, ensuring the highest standards of structural integrity and performance.
Discover how we can help - Get a quote today.
Customer Reviews
-
Superior Purity
Using Creative Biolabs' BsAb service in our research has facilitated our effector-cell studies. The common light chain approach they recommended resolved the purification bottlenecks and mispairing issues we encountered with previous workflows. - Dr. A*n. R. -
Structural Stability
Creative Biolabs helped us transition from a complex scFv-Fc format to a stable IgG-like structure. The AI-driven linker optimization was a critical factor that enhanced our dual-antigen binding affinity and overall molecule solubility. - Prof. S**h M.
FAQs
How do you prevent light-chain mispairing?
We utilize specialized molecular strategies and optimized scaffolds to ensure correct assembly. These methods significantly minimize the production of undesired side products during the expression and purification stages.
Can you produce BsAbs without an Fc region?
Yes, we generate various antibody fragments tailored for research. These formats are ideal for laboratory applications requiring rapid tissue penetration and shorter biological half-lives in experimental models.
Related Services
Antibody Discovery Services
Utilizing advanced phage display and hybridoma technologies to identify high-affinity lead candidates against diverse therapeutic and diagnostic research targets.
Learn More →Cell Line Development Service
Establishing high-yield, genetically stable mammalian cell lines through sophisticated vector optimization and high-throughput screening for reliable, long-term research-scale production.
Learn More →How to Contact Us
Creative Biolabs provides an end-to-end platform for the design, engineering, and production of high-performance Bispecific Antibodies. Our focus on heterodimerization precision, manufacturability, and structural integrity makes us the preferred partner for biotechnology and pharmaceutical researchers worldwide. If there is any question, please contact us for more information.
Reference
- Rees, Matthew et al. "Bispecific antibody targets and therapies in multiple myeloma." Frontiers in immunology vol. 15 1424925. 10 Oct. 2024. https://doi.org/10.3389/fimmu.2024.1424925
- Ma, Jiabing et al. "Bispecific Antibodies: From Research to Clinical Application." Frontiers in immunology vol. 12 626616. 5 May. 2021. https://doi.org/10.3389/fimmu.2021.626616
- Distributed under an Open Access license CC BY 4.0, without modification.
Download our brochureLoading case studies...
Online Inquiry